ASTRAZENECA PLC-SPONS ADR (AZN) Fundamental Analysis & Valuation

NYSE:AZN • US0463531089

Current stock price

185.78 USD
+1.71 (+0.93%)
At close:
185.78 USD
0 (0%)
After Hours:

This AZN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. AZN Profitability Analysis

1.1 Basic Checks

  • AZN had positive earnings in the past year.
  • AZN had a positive operating cash flow in the past year.
  • AZN had positive earnings in each of the past 5 years.
  • Each year in the past 5 years AZN had a positive operating cash flow.
AZN Yearly Net Income VS EBIT VS OCF VS FCFAZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

1.2 Ratios

  • With an excellent Return On Assets value of 8.96%, AZN belongs to the best of the industry, outperforming 90.16% of the companies in the same industry.
  • AZN has a better Return On Equity (21.01%) than 91.71% of its industry peers.
  • AZN has a Return On Invested Capital of 13.63%. This is amongst the best in the industry. AZN outperforms 92.75% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for AZN is in line with the industry average of 13.06%.
  • The 3 year average ROIC (12.48%) for AZN is below the current ROIC(13.63%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.96%
ROE 21.01%
ROIC 13.63%
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
AZN Yearly ROA, ROE, ROICAZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • The Profit Margin of AZN (17.41%) is better than 90.16% of its industry peers.
  • In the last couple of years the Profit Margin of AZN has grown nicely.
  • AZN has a Operating Margin of 23.86%. This is amongst the best in the industry. AZN outperforms 90.67% of its industry peers.
  • In the last couple of years the Operating Margin of AZN has grown nicely.
  • AZN has a better Gross Margin (81.31%) than 86.01% of its industry peers.
  • AZN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 23.86%
PM (TTM) 17.41%
GM 81.31%
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
AZN Yearly Profit, Operating, Gross MarginsAZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

4

2. AZN Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AZN is still creating some value.
  • The number of shares outstanding for AZN remains at a similar level compared to 1 year ago.
  • AZN has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, AZN has an improved debt to assets ratio.
AZN Yearly Shares OutstandingAZN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B
AZN Yearly Total Debt VS Total AssetsAZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • An Altman-Z score of 3.68 indicates that AZN is not in any danger for bankruptcy at the moment.
  • AZN's Altman-Z score of 3.68 is fine compared to the rest of the industry. AZN outperforms 73.58% of its industry peers.
  • AZN has a debt to FCF ratio of 3.42. This is a good value and a sign of high solvency as AZN would need 3.42 years to pay back of all of its debts.
  • The Debt to FCF ratio of AZN (3.42) is better than 89.64% of its industry peers.
  • AZN has a Debt/Equity ratio of 0.55. This is a neutral value indicating AZN is somewhat dependend on debt financing.
  • AZN has a worse Debt to Equity ratio (0.55) than 62.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.42
Altman-Z 3.68
ROIC/WACC1.48
WACC9.21%
AZN Yearly LT Debt VS Equity VS FCFAZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.3 Liquidity

  • A Current Ratio of 0.94 indicates that AZN may have some problems paying its short term obligations.
  • AZN's Current ratio of 0.94 is on the low side compared to the rest of the industry. AZN is outperformed by 84.46% of its industry peers.
  • AZN has a Quick Ratio of 0.94. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • AZN's Quick ratio of 0.72 is on the low side compared to the rest of the industry. AZN is outperformed by 83.42% of its industry peers.
Industry RankSector Rank
Current Ratio 0.94
Quick Ratio 0.72
AZN Yearly Current Assets VS Current LiabilitesAZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

5

3. AZN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 11.57% over the past year.
  • Measured over the past years, AZN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 17.91% on average per year.
  • AZN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.63%.
  • Measured over the past years, AZN shows a quite strong growth in Revenue. The Revenue has been growing by 17.15% on average per year.
EPS 1Y (TTM)11.57%
EPS 3Y11.21%
EPS 5Y17.91%
EPS Q2Q%1.44%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%

3.2 Future

  • AZN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.35% yearly.
  • Based on estimates for the next years, AZN will show a small growth in Revenue. The Revenue will grow by 6.31% on average per year.
EPS Next Y15.5%
EPS Next 2Y13.99%
EPS Next 3Y12.58%
EPS Next 5Y11.35%
Revenue Next Year7.13%
Revenue Next 2Y6.67%
Revenue Next 3Y6.43%
Revenue Next 5Y6.31%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AZN Yearly Revenue VS EstimatesAZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
AZN Yearly EPS VS EstimatesAZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

7

4. AZN Valuation Analysis

4.1 Price/Earnings Ratio

  • AZN is valuated rather expensively with a Price/Earnings ratio of 20.13.
  • Based on the Price/Earnings ratio, AZN is valued cheaper than 82.38% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.50. AZN is valued slightly cheaper when compared to this.
  • The Price/Forward Earnings ratio is 17.42, which indicates a rather expensive current valuation of AZN.
  • Based on the Price/Forward Earnings ratio, AZN is valued cheaply inside the industry as 80.31% of the companies are valued more expensively.
  • AZN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.67.
Industry RankSector Rank
PE 20.13
Fwd PE 17.42
AZN Price Earnings VS Forward Price EarningsAZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • AZN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AZN is cheaper than 82.38% of the companies in the same industry.
  • AZN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AZN is cheaper than 80.31% of the companies in the same industry.
Industry RankSector Rank
P/FCF 33.23
EV/EBITDA 15.63
AZN Per share dataAZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • AZN has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as AZN's earnings are expected to grow with 12.58% in the coming years.
PEG (NY)1.3
PEG (5Y)1.12
EPS Next 2Y13.99%
EPS Next 3Y12.58%

7

5. AZN Dividend Analysis

5.1 Amount

  • AZN has a Yearly Dividend Yield of 1.73%. Purely for dividend investing, there may be better candidates out there.
  • AZN's Dividend Yield is rather good when compared to the industry average which is at 0.79. AZN pays more dividend than 91.71% of the companies in the same industry.
  • AZN's Dividend Yield is comparable with the S&P500 average which is at 1.89.
Industry RankSector Rank
Dividend Yield 1.73%

5.2 History

  • The dividend of AZN has a limited annual growth rate of 3.33%.
  • AZN has paid a dividend for at least 10 years, which is a reliable track record.
  • AZN has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)3.33%
Div Incr Years1
Div Non Decr Years11
AZN Yearly Dividends per shareAZN Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3

5.3 Sustainability

  • 48.62% of the earnings are spent on dividend by AZN. This is a bit on the high side, but may be sustainable.
  • The dividend of AZN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP48.62%
EPS Next 2Y13.99%
EPS Next 3Y12.58%
AZN Yearly Income VS Free CF VS DividendAZN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B
AZN Dividend Payout.AZN Dividend Payout, showing the Payout Ratio.AZN Dividend Payout.PayoutRetained Earnings

AZN Fundamentals: All Metrics, Ratios and Statistics

ASTRAZENECA PLC-SPONS ADR

NYSE:AZN (3/24/2026, 8:15:01 PM)

After market: 185.78 0 (0%)

185.78

+1.71 (+0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-10
Earnings (Next)04-29
Inst Owners37.6%
Inst Owner Change1.22%
Ins Owners0.03%
Ins Owner Change0%
Market Cap288.11B
Revenue(TTM)58.74B
Net Income(TTM)10.22B
Analysts82.94
Price Target208.03 (11.98%)
Short Float %N/A
Short Ratio0.46
Dividend
Industry RankSector Rank
Dividend Yield 1.73%
Yearly Dividend3.21
Dividend Growth(5Y)3.33%
DP48.62%
Div Incr Years1
Div Non Decr Years11
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.02%
Min EPS beat(2)-1.5%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)0.45%
Min EPS beat(4)-7.49%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.6%
EPS beat(12)7
Avg EPS beat(12)1.6%
EPS beat(16)11
Avg EPS beat(16)2.81%
Revenue beat(2)0
Avg Revenue beat(2)-1.57%
Min Revenue beat(2)-2.88%
Max Revenue beat(2)-0.26%
Revenue beat(4)0
Avg Revenue beat(4)-3.05%
Min Revenue beat(4)-5.08%
Max Revenue beat(4)-0.26%
Revenue beat(8)3
Avg Revenue beat(8)-0.6%
Revenue beat(12)4
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-0.82%
PT rev (1m)2.6%
PT rev (3m)116.59%
EPS NQ rev (1m)0.06%
EPS NQ rev (3m)95.69%
EPS NY rev (1m)0.12%
EPS NY rev (3m)99.3%
Revenue NQ rev (1m)0.64%
Revenue NQ rev (3m)0.18%
Revenue NY rev (1m)0.26%
Revenue NY rev (3m)1.3%
Valuation
Industry RankSector Rank
PE 20.13
Fwd PE 17.42
P/S 4.9
P/FCF 33.23
P/OCF 19.77
P/B 5.92
P/tB N/A
EV/EBITDA 15.63
EPS(TTM)9.23
EY4.97%
EPS(NY)10.66
Fwd EY5.74%
FCF(TTM)5.59
FCFY3.01%
OCF(TTM)9.4
OCFY5.06%
SpS37.88
BVpS31.38
TBVpS-6.72
PEG (NY)1.3
PEG (5Y)1.12
Graham Number80.73
Profitability
Industry RankSector Rank
ROA 8.96%
ROE 21.01%
ROCE 16.8%
ROIC 13.63%
ROICexc 14.63%
ROICexgc 59.47%
OM 23.86%
PM (TTM) 17.41%
GM 81.31%
FCFM 14.76%
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
ROICexc(3y)13.49%
ROICexc(5y)11.39%
ROICexgc(3y)81.92%
ROICexgc(5y)83.55%
ROCE(3y)15.36%
ROCE(5y)12.92%
ROICexgc growth 3Y-25.55%
ROICexgc growth 5Y0.81%
ROICexc growth 3Y9.13%
ROICexc growth 5Y9.72%
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
F-Score7
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.42
Debt/EBITDA 1.36
Cap/Depr 103%
Cap/Sales 10.05%
Interest Coverage 10.65
Cash Conversion 73.79%
Profit Quality 84.79%
Current Ratio 0.94
Quick Ratio 0.72
Altman-Z 3.68
F-Score7
WACC9.21%
ROIC/WACC1.48
Cap/Depr(3y)80.57%
Cap/Depr(5y)64.46%
Cap/Sales(3y)8.93%
Cap/Sales(5y)7.69%
Profit Quality(3y)99.49%
Profit Quality(5y)775.68%
High Growth Momentum
Growth
EPS 1Y (TTM)11.57%
EPS 3Y11.21%
EPS 5Y17.91%
EPS Q2Q%1.44%
EPS Next Y15.5%
EPS Next 2Y13.99%
EPS Next 3Y12.58%
EPS Next 5Y11.35%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%
Revenue Next Year7.13%
Revenue Next 2Y6.67%
Revenue Next 3Y6.43%
Revenue Next 5Y6.31%
EBIT growth 1Y10.05%
EBIT growth 3Y16.67%
EBIT growth 5Y26.09%
EBIT Next Year25.86%
EBIT Next 3Y14.6%
EBIT Next 5Y10.4%
FCF growth 1Y19.18%
FCF growth 3Y6.21%
FCF growth 5Y31.64%
OCF growth 1Y22.88%
OCF growth 3Y14.12%
OCF growth 5Y24.88%

ASTRAZENECA PLC-SPONS ADR / AZN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ASTRAZENECA PLC-SPONS ADR?

ChartMill assigns a fundamental rating of 6 / 10 to AZN.


What is the valuation status for AZN stock?

ChartMill assigns a valuation rating of 7 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Undervalued.


How profitable is ASTRAZENECA PLC-SPONS ADR (AZN) stock?

ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.


Can you provide the PE and PB ratios for AZN stock?

The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 20.13 and the Price/Book (PB) ratio is 5.92.


What is the expected EPS growth for ASTRAZENECA PLC-SPONS ADR (AZN) stock?

The Earnings per Share (EPS) of ASTRAZENECA PLC-SPONS ADR (AZN) is expected to grow by 15.5% in the next year.